New treatments for breast cancer: Breakthroughs for patient care or just steps in the right direction?

Annals of Oncology

Volumn 9, Issue 9, 1998, Pages 973-976

  Goldhirsch, A ^a   Coates, A S ^b   Castiglione Gertsch, M ^b   Gelber, R D ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NONE

Author keywords

Adjuvant paclitaxel; Breast cancer; Herceptin(TM); Prevention; Raloxifene; Tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; HUMANIZED HER 2 ANTIBODY; MONOCLONAL ANTIBODY; PACLITAXEL; RALOXIFENE; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEVER; GENE OVEREXPRESSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NOTE; ONCOGENE NEU; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031762083     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008436810268     Document Type: Note

References (13)

1. Wickerham DL, Costantino JC, Fisher B et al. The initial results from NSABP protocol P-1: A clinical trial to determine the worth of tamoxifen for preventing breast cancer in women at increased risk. Proc Am Soc Clin Oncol 1998; 17 (supplemental abstr).
2. Jordan VC, Glusman JE, Eckert S et al. Incident primary breast cancers arc reduced by raloxifene: Integrated data from multicenter, double-blind, randomized trials in ∼ 12,000 postmenopausal women. Proc Am Soc Clin Oncol 1998; 17: 122a (Abstr 466).
3. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7.
4. Cuzick J. Chemoprevention of breast cancer with tamoxifen. IARC Sci Publ 1996; 136: 95-109.
5. Mannucci PM, Bettega D, Chantarangkul V et al. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 1996; 156: 1806-10.
6. Henderson IC, Berry D, Demetri G et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 1998; 17: 101a (Abstr 390A).
7. International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996; 14: 1885-94.
8. Hutchins L, Green S, Ravdin P et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial int 0102. Proc Am Soc Clin Oncol 1998; 17: 1a (Abstr 2).
9. Levine M, Bramwell V, Pritchard KI et al. A randomized trial of cyclophosphamide, epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, fluorouracil in premenopausal women with node positive breast cancer. J Clin Oncol 1998 (in press).
10. Goldhirsch A, Coates AS, Colleoni M et al. for the International Breast Cancer Study Group. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. J Clin Oncol 1998; 16: 1358-62.
11. Cobleigh MA, Vogel CL, Tripathy D et al. Efficacy and safety of Herceptin™ (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998; 17: 97a (Abstr 376).
12. Slamon D, Leyland-Jones B, Shak S et al. Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998; 17: 98a (Abstr 377).
13. Pietras RJ, Fendly BM, Chazin VR et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 7: 1829 38.